SIRPant

Start-up company spearheading the development of macrophage-based cell therapies for the treatment of hard tumors.

SIRPant partnered with Merz on a brand development project to introduce the company to investors in order to meet seed round funding objectives to initiate a 10-patient phase 1 clinical trial at Emory University Hospital.